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ABSTRACT (150-250 words) 
 
Purpose: Perhexiline is a prophylactic anti-ischaemic agent with weak calcium 
antagonist effect which has been increasingly utilized in the management of 
refractory angina. The metabolic clearance of perhexiline is modulated by CYP2D6 
metaboliser status and stereoselectivity. The current study sought to determine (1) 
whether the acute accumulation of perhexiline in the myocardium is stereoselective, 
and (2) to investigate the relationship between duration of short-term therapy and the 
potential stereoselective effects of perhexiline within myocardium.  
 
Method: Patients (n=129) from the active arm of a randomised controlled trial of 
preoperative perhexiline in cardiac surgery, were treated with oral perhexiline for a 
median of 9 days. Correlates of atrial and ventricular concentrations of enantiomers 
were sought via univariate followed by multivariate analyses.  
 
Results: Myocardial uptake of both (+) and (-)-perhexiline was greater in ventricles 
than atria, and there was more rapid clearance of (-) than (+)-perhexiline. The main 
determinants of atrial uptake of both (+) and (-)-perhexiline were the plasma 
concentrations [(+)-perhexiline: β=-0.256, p=0.015; (-)-perhexiline: β=-0.347, 
p=0.001] and patients' age [(+)-perhexiline: β=0.3, p=0.004; (-)-perhexiline: β=0.288, 
p=0.005]. Atrial uptake of (+)-enantiomer also varied directly with duration of therapy 
(r=0.29, p=0.004), while atrial uptake of (-)-perhexiline varied inversely with 
simultaneous heart rate (r=-0.22, p=0.03).   
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Conclusion: (1) Uptake of both perhexiline enantiomers into atrium is greater with 
advanced age, and displays evidence of both saturability and minor stereoselectivity. 
(2) Atrial uptake of (-) perhexiline may selectively modulate heart rate reduction.  
 
(Word count: 235 words) 
5 
 
INTRODUCTION 
 
Perhexiline is a metabolic modulating agent that was first introduced into clinical 
practice as a prophylactic anti-anginal drug in the 1970s. It exerts multiple effects 
which increase efficiency of myocardial metabolism: amongst these it is known to 
inhibit mitochondrial carnitine palmitoyl transferase-1 [1], potentially resulting in a 
shift from fatty acid to glucose utilisation with more adenosine triphosphate 
production per unit oxygen consumption.  
 
Despite the considerable clinical efficacy of perhexiline in prophylaxis of exertional 
angina [2, 3], its use declined because of the substantial risk of hepato- and neuro-
toxicity during chronic therapy [4-6]. However, it emerged that this toxicity reflected 
drug accumulation in plasma [7] which in turn resulted from inter-individual variability 
in CYP2D6-mediated metabolism [8, 9]. With widespread availability of therapeutic 
drug monitoring [10, 11] and greater understanding of its potential widespread utility 
for disorders of cardiac energetics [12], the clinical use of perhexiline is now 
increasing.  
 
Kinetically, perhexiline is a lipophilic drug well absorbed from the gastrointestinal 
tract. It is highly protein bound and has a large volume of distribution. As it is subject 
to hepatic metabolism by CYP2D6, the plasma half-life of perhexiline ranges from 
several hours to several weeks [7, 13].  
 
A number of studies have specifically evaluated short-term utility of perhexiline in the 
management of potential cardiac crises, such as the management of high risk 
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patients with unstable ischaemia and for cardioprotection during coronary 
revascularisation [14-16]. The recently reported CASPER trial evaluated its use as 
an adjunct to myocardial protection in patients undergoing coronary artery surgery 
but found no clear-cut beneficial effect of prophylactic perhexiline therapy [17]. 
During this trial, atrial and ventricular myocardial biopsies were taken at the time of 
surgery. We have previously reported on analyses of these samples to evaluate the 
relationship between plasma and myocardial drug concentrations [18]. The objective 
of the current analysis stems from our recent observation that the effects of racemic 
perhexiline may result from unequal steady-state concentrations of its two 
enantiomers [19].  
 
In human liver microsomes, the intrinsic clearance of (-)-perhexiline is greater than 
that of the (+)-enantiomer [20], which explains the greater clearance rate of (-)-
perhexiline at steady state in patients receiving racemic perhexiline [21]. 
Interestingly, it appears from studies in a rat model, that the safety of the two 
enantiomers may vary, with greater hepatotoxicity associated with the (+)-
enantiomer [22].  
 
Therefore, we have re-evaluated the CASPER data in order to determine: 
(1) Whether atrial and ventricular myocardial accumulation of perhexiline during 
short-term treatment are stereoselective, and whether this reflects similar trends in 
plasma enantiomer concentrations. 
(2) The relationship between duration of (short-term) perhexiline therapy and the 
potential for stereoselective effects of perhexiline within the myocardium.  
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METHODS 
 
Data were mainly derived from patients in the active treatment arm of the CASPER 
(Coronary Artery Surgery with PERhexiline therapy) trial (NCT00845364). In brief, 
this was a double-blind, randomized, placebo-controlled clinical trial evaluating 
whether preoperative oral perhexiline to improve myocardial protection in patients 
undergoing cardiac surgery. Non-diabetic patients, who were not taking CYP2D6 
inhibitors, undergoing first time coronary artery bypass graft surgery were 
randomized to either perhexiline maleate or placebo for at least five days prior to 
surgery. All patients received the following medication regimen: 200mg twice daily 
for three days then 100mg twice daily until the morning of the surgery [17]. On-
treatment heart rate was determined by preoperative resting electrocardiogram. 
 
Following induction of anaesthesia but prior to commencing surgery, the 
haemodynamic status of each patient, including arterial pressures and cardiac index 
were determined. Plasma collected at this timepoint was centrifuged and stored at -
80°C; this has previously been used to phenotype patients for CYP2D6 metaboliser 
status [17] according to the plasma concentration ratios of perhexiline 
monohydroxylated metabolite to parent drug [13]. During preparation for 
cardiopulmonary bypass but prior to aortic cross-clamping, right atrial and left 
ventricular myocardial biopsies were obtained, as previously described [17]. These 
biopsies were initially snap-frozen in liquid nitrogen and stored at -80°C, then later 
digested in 0.15 M of phosphate buffer solution (pH 6.0) using a homogenizer and 
tissue grinder to form a suspension (approximately 100mg tissue in 5ml buffer). 
Plasma and myocardial perhexiline enantiomer concentrations were determined 
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utilizing a modification of a previously described HPLC assay [23]. Thresholds for 
detection of myocardial (+) and (-) perhexiline were 0.01mg/L with sensitivity and 
accuracy between 0.01 and 2.00mg/L with intra-assay coefficients of variation and 
bias <20% at 0.01mg/L. [23]  
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ANALYSIS OF RESULTS 
 
1. Determination of relative uptake of enantiomers 
 
Concentrations of each enantiomer in atrial and ventricular myocardium were 
correlated with plasma enantiomer concentrations to derive tissue to plasma 
concentration ratios.  
 
 Potential stereo-selectivity of uptake was evaluated via determination of:  
I. Differential (+) to (-) enantiomer ratio in myocardium versus plasma (in 
order to determine whether uptake, rather than clearance, might 
engender stereoselective myocardial effects). 
II. Percentage of (+)-enantiomer concentrations in plasma and 
myocardium, in relation to time (in order to determine the net effects of 
stereoselective kinetics on the myocardial uptake of the drug).  
 
 
2. Identification of determinants or correlates of myocardial (+) and (-)-
perhexiline uptake 
 
Univariate (evaluated utilizing Spearman’s correlation) followed by 
multivariate analyses were utilized for assessment of the atrial uptake of 
enantiomers. Parameters evaluated were plasma concentration, metaboliser 
status, age, weight, duration of therapy, resting heart rate, creatinine 
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clearance, and cardiac index. Multivariate backward stepwise analyses were 
performed using statistical software SPSS (version 20, Chicago).  
 
3. Data from poor metabolisers (n=7) were excluded from analysis (unless 
specified otherwise) because of potential for differential clearance 
mechanisms and non-attainment of near-steady state kinetics. 
 
4. Data are expressed throughout as mean ± SD for normally distributed 
parameters and median (interquartile range) for skewed data.  
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RESULTS 
 
1. Patient demographics: metaboliser status and absence of dose titration 
 
129 patients from the active arm of CASPER trial were included and their clinical 
characteristics are summarised in Table 1. While patients had well-preserved renal 
function, their pre-treatment cardiac function is not known, with formal estimation of 
cardiac indices and heart rates performed following the induction of anaesthesia for 
surgery; these data therefore reflect the potential interaction of perhexiline and pre-
treatment status. However, the generally low cardiac indices in these patients imply 
some degree of systolic left ventricular dysfunction at least at the time of 
measurement. The median plasma concentrations of perhexiline at the time of blood 
sampling were 0.27mg/L (IQR: 0.13 - 0.47), with approximately one third of patients 
having subtherapeutic levels (i.e. <0.15mg/L).  
 
Figure 1 examines the relationship between plasma cis-OH-perhexiline/ perhexiline 
ratio (used to categorise metaboliser status) and plasma perhexiline concentration at 
the time of surgery. It is apparent that there was substantial variability in racemic 
perhexiline concentrations, such that therapeutic concentrations were not generally 
attained in rapid metabolisers. There were a total of 7 poor metabolisers, all of whom 
attained therapeutic or potentially toxic perhexiline concentrations.  
 
2. Myocardial concentrations of enantiomers 
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The relationships between plasma and atrial or ventricular concentrations of (+) and 
(-)-perhexiline are depicted in Figures 2A and 2B respectively. There were strong 
direct correlations for both enantiomers, with slightly greater concentrations of both 
enantiomers in ventricle than atrium (p<0.001 for both, Spearman's test).  
 
The impact of metaboliser status on these plasma: myocardial concentration 
relationships is summarised in Table 2. All but two plasma enantiomer 
concentrations were >0.02mg/L. In summary, plasma concentrations of (+)-
perhexiline tended to be greater than those of (-)-perhexiline for both plasma and 
myocardium, irrespective of metaboliser status.  
 
We next sought to determine whether stereoselective clearance of perhexiline and/or 
of its uptake into myocardium might vary with duration of therapy. The proportion of 
(+)-perhexiline in plasma did not vary significantly with duration of therapy (Figure 
3A), while that in atria increased significantly (p=0.004) with time (Figure 3B). Thus 
the ratio of (+)-perhexiline in the atrium to that in plasma tended to increase 
progressively (r=0.19, p=0.07). 
 
Concentrations of both (+)- and (-)-perhexiline into the ventricle increased 
significantly with time (p=0.005 and 0.004 respectively, Figure 4), with no significant 
difference between the enantiomers.  
 
3. Multivariate correlates of uptake of enantiomer 
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Table 3 summarizes atrial: plasma concentration ratios, with all patients (excluding 
poor metabolisers) evaluated. Plasma perhexiline concentration was a strong 
negative correlate and age was a positive correlate of this ratio for both enantiomers.  
Uptake of (-)-perhexiline also varied inversely with simultaneous heart rate. Similar 
trends were also apparent with univariate correlations (Figure 5).  
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DISCUSSIONS 
 
The current analyses complement our previously published evaluation of the uptake 
of racemic perhexiline into the human myocardium [18]. It is apparent from the 
current studies that the perhexiline dosing regimen utilized, with inadequate time 
available for adjustment of dosage on the basis of metaboliser status, led to wide 
variability in plasma and myocardial drug concentrations, but nonetheless, allowed 
exploration of determinants of myocardial uptake of perhexiline enantiomers.  
 
The main findings of the current analysis are that: 
1. Plasma concentrations of (+) or (-)-perhexiline and the corresponding 
myocardial concentrations are closely and directly correlated.  
2. Just as plasma (+)-enantiomer concentration exceeds that of (-)-enantiomer, 
similar trends are present in myocardium, especially atrial muscle.  
3. Myocardial uptake of each enantiomer also depends on plasma drug 
concentrations and patients' age, where a strong inverse relationship is 
present.  
4. Atrial uptake of (+)-perhexiline also varies with on duration of therapy.  
5. Atrial uptake of (-)-perhexiline varies inversely with simultaneous heart rate.  
 
These findings carry a number of important implications regarding the myocardial 
handling and effects of perhexiline enantiomers.  
 
The higher concentrations of (+) than (-)-enantiomer in plasma are consistent with 
more rapid clearance of the latter. These data are consistent with previous 
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publications regarding the stereoselective clearance of perhexiline [20, 21]. On the 
other hand, myocardial concentration ratios of the enantiomers generally parallel 
with those in plasma, suggesting absence of major stereoselectivity in myocardial 
uptake. The exception to this is the small but statistically significant increase in the 
proportion of (+)-enantiomer in the atrial myocardium with time (Figure 3B). These 
data suggest that myocardial uptake and efflux of (-)-perhexiline may be slightly 
more rapid than that of the (+)-enantiomer. 
 
The relatively prolonged time required to reach steady-state perhexiline 
concentrations in the ventricular myocardium may reflect greater distribution into 
mitochondria [24], known to represent a site of intracellular drug accumulation for 
perhexiline in hepatocytes [25].  
 
As regards the interactions between advanced age and cardiac uptake of the 
enantiomers, the current data suggest that uptake of both perhexiline enantiomers is 
greater in older patients, perhaps related to decreased skeletal muscle mass. Indeed 
we have previously also shown that steady-state dosage requirements for 
perhexiline tend to fall with age [26], and in the current study plasma perhexiline 
concentrations increased with patient age (r=0.24, p=0.029). Together, these data 
suggest that elderly individuals may benefit from perhexiline therapy despite 
apparently borderline subtherapeutic plasma drug levels.  
 
Finally, atrial uptake of (-)-perhexiline varied inversely with concurrent heart rate. 
This is not consistent with the usual accelerating effect of tachycardia on myocardial 
drug uptake [27] and suggests another mechanism for association. Perhexiline is a 
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weak L-type calcium antagonist [28, 29], although its effects on the myocardium 
have undergone only limited study. The IC50 for inhibition of calcium fluxes in chick 
embryo ventricular myocardium by racemic perhexiline was 8.3 x 10-7 M [28]. In the 
current study, atrial concentrations of (-)-perhexiline approximated to these values. It 
is therefore possible that the calcium antagonist effect of rac-perhexiline is mediated 
primarily by the (-)-enantiomer, despite the current limitation of the understanding of 
pharmacological actions of the perhexiline enantiomers.  
 
The current study has several limitations. Most importantly, correlation with cardiac 
effects of perhexiline is limited by the absence of true pre-treatment data and that 
evaluation of the effects of the enantiomers is only extrapolated on the basis of 
administration of rac-perhexiline. Second, myocardial drug content after a median of 
9 days of therapy reflects both uptake into and efflux from the myocardium, and 
there is no way to determine the precise component of each, given that steady state 
has not been reached. Finally, the full implications of the widely variable plasma 
perhexiline concentrations on variability in drug uptake cannot be fully understood 
without a strategy of multiple drug dosing per patient.  
 
The current results also need to be related to the clinical context. Recently we have 
reported on acute loading of perhexiline in patients with severe ischaemia [14, 15]. 
The current data are consistent with the idea that there may be early onset of 
cardioprotective effects, especially in the elderly, at a time when plasma drug 
concentrations are notionally subtherapeutic. Furthermore, the data regarding heart 
rate correlations should stimulate evaluation of whether the calcium antagonist 
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effects of perhexiline can be dissociated from its “metabolic” cardioprotective effects 
[30, 31], by selective administration of the (+)-enantiomer.  
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TABLE AND FIGURE LEGENDS 
 
Table 1:  
Clinical characteristics of patients (n=129) 
a. Expressed as median (interquartile range) 
┼ On treatment, whilst under anaesthesia immediately prior to surgery.  
 
Table 2:  
Perhexiline enantiomer concentrations in plasma, atrial and ventricular myocardium 
across all metabolic phenotypes. Metabolizer status was defined by the ratio of 
plasma concentrations of cis-hydroxyperhexiline to perhexiline. Poor metabolizer 
was defined by a ratio of ≤ 0.3; intermediate metabolizer was defined by a ratio of 
0.3 to 2.5; extensive metabolizer was defined by a ratio of 2.5 to 20; and ultra-rapid 
metabolizer was defined by a ratio of ≥ 20. 
Data expressed as mean ± SD or median (interquartile range). 
* p<0.05 vs antipode (Wilcoxon); ∆ p<0.005 vs atrial:plasma ratio  
 
Table 3:  
Correlates of the atrial: plasma ratio (net uptake) of each enantiomer on multivariate 
analyses (excluding poor metabolisers). 
 
Figure 1:  
The relationship between rate of perhexiline metabolism (expressed as cis-OH-
perhexiline/ perhexiline ratio) and plasma perhexiline enantiomer concentrations at 
the time of surgery.  
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Data to the left of the dashed line (ratio <0.3) correspond to "poor metaboliser" 
status.    
 
Figure 2: 
Correlations between plasma and myocardial (atrial and ventricular) concentrations 
for (A) (+)-perhexiline, and (B) (-)-perhexiline. Spearman's correlations are shown. 
 
Figure 3:  
Variations in the percentage of (+)-perhexiline in (A) plasma and (B) atrial 
myocardium relative to duration of therapy. Spearman's correlations are shown.  
 
Figure 4:  
Impact of duration of treatment on concentrations of perhexiline enantiomers in 
ventricular myocardium. Spearman's correlations are shown. 
 
Figure 5:  
Univariate comparisons (Spearman's correlation) between (A) patients' age and (B) 
resting heart rate and uptake ratio of each enantiomer into atrial myocardium.  
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Table 1:  
Clinical characteristics of patients (n=129) 
a. Expressed as median (interquartile range) 
┼ On treatment, whilst under anaesthesia immediately prior to surgery.  
 
Parameters  
Age (years) a 66 (58-73) a 
Weight (kg) 83 ± 14 
Creatinine clearance (ml/min) a 70 (60 - 85) a 
Baseline cardiac index 2.04 (1.78 - 2.34) a 
Resting heart rate (beats per minute) ┼ 59 ± 10 
Duration of therapy (days)a  9 (6 - 12) a 
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Table 2:  
Perhexiline enantiomer concentrations in plasma, atrial and ventricular myocardium 
across all metabolic phenotypes. Metabolizer status was defined by the ratio of 
plasma concentrations of cis-hydroxyperhexiline to perhexiline. Poor metabolizer 
was defined by a ratio of ≤ 0.3; intermediate metabolizer was defined by a ratio of 
0.3 to 2.5; extensive metabolizer was defined by a ratio of 2.5 to 20; and ultra-rapid 
metabolizer was defined by a ratio of ≥ 20. 
Data expressed as mean ± SD or median (interquartile range). 
* p<0.05 vs antipode (Wilcoxon); ∆ p<0.005 vs atrial:plasma ratio  
 
Metaboliser 
status 
Plasma 
concentrations 
(mg/L) 
Atrial 
concentrations 
(mg/kg) 
Ventricular 
concentrations 
(mg/kg) 
(+) (-) (+) (-) (+) (-) 
Poor 
metaboliser 
n=7 n=3 n=1 
0.67 ± 
0.32 * 
0.48 ± 
0.21 
16.57 ± 
6.57 
13.22 ± 
4.89 
17.5 12.5 
Intermediate 
metaboliser 
 
n =28 n =19 n =6 
0.28 
(0.24-
0.37) * 
0.23 
(0.18-
0.29) 
6.17 
(5.45-
8.16) * 
5.11 
(4.28-
6.58) 
11.07 ± 
5.41∆ 
9.08 ± 
4.54 ∆ 
Extensive 
metabolisers 
n =85 n =64 n =21 
0.11 
(0.07-
0.08 
(0.05-
2.77 
(1.50-
2.17 
(1.26-
5.16 ± 
2.48 ∆ 
3.55 ± 
2.17 ∆ 
26 
 
0.17) * 0.13) 3.99) * 3.24)  
Ultrarapid 
metabolisers 
n =9 n =8 n =2 
0.03 
(0.026-
0.037) * 
0.023 
(0.017-
0.027) 
0.84 ± 
0.31 
0.623 ± 
0.314 
3.41 ± 
0.41 
1.56 ± 
2.21 
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Table 3:  
Correlates of the atrial: plasma ratio (net uptake) of each enantiomer on multivariate 
analyses (excluding poor metabolisers). 
 
Determinant Correlates β 
coefficient 
p-value 
Atrial:plasma ratio 
of (+)-perhexiline 
Plasma (+)-perhexiline concentration -0.256 0.015 
Duration of therapy 0.228 0.025 
Age 0.300 0.004 
Atrial: plasma ratio 
of (-)-perhexiline 
Plasma (-)-perhexiline concentration -0.347 0.001 
Age 0.288 0.005 
On-treatment resting heart rate -0.240 0.015 
 
